Baseline Lipoprotein Lipids and Low-Density Lipoprotein Cholesterol Response to Prescription Omega-3 Acid Ethyl Ester Added to Simvastatin Therapy

American Journal of Cardiology

Volumn 105, Issue 10, 2010, Pages 1409-1412

  Maki, Kevin C ^a   Dicklin, Mary R ^a   Davidson, Michael H ^b,e   Doyle, Ralph T ^c   Ballantyne, Christie M ^d  

^a Provident Clinical Research   (United States)

^b RADIANT RESEARCH   (United States)

^c GLAXOSMITHKLINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; TREATMENT OUTCOME;

EID: 77951667873     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.063     Document Type: Article

References (30)

1. Harris W.S., Ginsberg H., Arunakul N., Shachter N.S., Windsor S.L., Adams M., Berglund L., and Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 4 (1997) 385-391
2. Harris W.S., Lu G., Rambjør G.S., Wålen A.I., Ontko J.A., Cheng Q., and Windsor S.L. Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases. Am J Clin Nutr 66 (1997) 254-260
3. Nordøy A., Bønaa K.H., Nilsen H., Berge R.K., Hansen J.B., and Ingebretsen O.C. Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 243 (1998) 163-170
4. Nordøy A., Hansen J.B., Brox J., and Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 11 (2001) 7-16
5. Durrington P.N., Bhatnagar D., Mackness M.I., Morgan J., Julier K., Khan M.A., and France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 85 (2001) 544-548
6. Chan D.C., Watts G.F., Barrett P.H.R., Beilin L.J., Redgrave T.G., and Mori T.A. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 51 (2002) 2377-2386
7. Chan D.C., Watts G.F., Mori T.A., Barrett P.H.R., Redgrave T.G., and Beilin L.J. Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am J Clin Nutr 77 (2003) 300-307
8. Ginsberg H.N. Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 87 (2001) 1174-1180
9. Davidson M.H., Stein S.E., Bays H.E., Maki K.C., Doyle R.T., Shalwitz R.A., Ballantyne C.M., and Ginsberg H.N. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007) 1354-1367
10. Barter P., and Ginsberg H.N. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol 102 (2008) 1040-1045
11. Maki K.C., McKenney J.M., Reeves M.S., Lubin B.C., and Dicklin M.R. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 102 (2008) 429-433
12. Maki K.C., Lubin B.C., Reeves M.S., Dicklin M.R., and Harris W.S. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol 3 (2009) 33-38
13. Bays H., McKenney J., Maki K.C., Doyle R., Carter R.N., and Stein E. Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc 85 (2010) 122-128
14. Sullivan D.R., Sanders T.A., Trayner I.M., and Thompson G.R. Paradoxical elevation of LDL apoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis 61 (1986) 129-134
15. Pownall H.J., Brauchi D., Kilinc C., Osmundsen K., Pao Q., Payton-Ross C., Gotto Jr. A.M., and Ballantyne C.M. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis 143 (1999) 285-297
16. Calabresi L., Donati D., Pazzucconi F., Sirtori C.R., and Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis 148 (2000) 387-396
17. McKenney J.M., and Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 27 (2007) 715-728
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
19. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., and Rimm E.B. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 (2005) 3375-3383
20. Liu J., Sempos C.T., Donahue R.P., Dorn J., Trevisan M., and Grundy S.M. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 98 (2006) 1363-1368
21. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., and Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119 (2009) 931-939
22. Kastelein J.J., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., Deedwania P., Olsson A.G., Boekholdt S.M., Demicco D.A., Szarek M., LaRosa J.C., Pedersen T.R., Grundy S.M., TNT Study Group, and IDEAL Study Group. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
23. Robinson J.G., Wang S., Smith B.J., and Jacobson T.A. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53 (2009) 316-322
24. Schoonjans K., Staels B., and Auwex J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37 (1996) 907-925
25. Swahn E., von Schenck H., and Olsson A.G. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin Drug Invest 15 (1998) 473-482
26. Olivieri O., Martinelli N., Sandri M., Bassi A., Guarini P., Trabetti E., Pizzolo F., Girelli D., Friso S., Pignatti P.F., and Corrocher R. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "Insulin-Resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. Clin Chem 51 (2005) 360-367
27. Davidson M.H., Maki K.C., Bays H.E., Carter R., and Ballantyne C.M. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. J Clin Lipidol 3 (2009) 333-320
28. Huff M.W., and Telford D.E. Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein. Arteriosclerosis 9 (1989) 58-66
29. Ginsberg H.N., Le N.-A., Goldberg I.J., Gibson J.C., Rubinstein A., Wang-Iverson P., Norum R., and Brown W.V. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78 (1986) 1287-1295
30. Harris W.S., Miller M., Tighe A.P., Davidson M.H., and Schaefer E.J. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197 (2008) 12-24